Mycophenolic acid
- Generic Name
- Mycophenolic acid
- Brand Names
- Myfortic
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20O6
- CAS Number
- 24280-93-1
- Unique Ingredient Identifier
- HU9DX48N0T
- Background
Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacroli...
- Indication
Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.
- Associated Conditions
- Kidney Transplant Rejection
- Associated Therapies
- -
Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 194
- Registration Number
- NCT01079143
- Locations
- 🇫🇷
Novartis Investigative Site, Vandoeuvre Les Nancys, France
Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 16
- Registration Number
- NCT01053221
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 44
- Registration Number
- NCT01018914
Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2009-10-19
- Lead Sponsor
- Qualitix Clinical Research Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT00997412
Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2011-09-15
- Lead Sponsor
- Armin Goralczyk
- Target Recruit Count
- 29
- Registration Number
- NCT00890253
- Locations
- 🇩🇪
University Medical Center Goettingen, Goettingen, Germany
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
- Conditions
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 44
- Registration Number
- NCT00866684
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Medizinische Klinik IV, Erlangen, Bavaria, Germany
🇩🇪Universitätsklinikum Münster, Klinik und Poliklinik für Hautkrankheiten, Münster, North Rhine-Westphalia, Germany
🇩🇪Universitätsklinikum Münster, Med. Klinik und Poliklinik D, Münster, North Rhine-Westphalia, Germany
Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)
- Conditions
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2008-05-15
- Lead Sponsor
- Foothills Medical Centre
- Target Recruit Count
- 110
- Registration Number
- NCT00676221
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
- Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 23
- Registration Number
- NCT00652834
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
- Conditions
- Interventions
- Drug: fludarabine phosphateDrug: Mycophenolic AcidDrug: tacrolimusRadiation: total-body irradiationProcedure: bone marrow transplantationProcedure: reduced intensity allogeneic hematopoietic stem cell transplantationProcedure: quality-of-life assessmentOther: laboratory biomarker analysisOther: flow cytometryProcedure: biopsy
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00622895
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 21
- Registration Number
- NCT00585468
- Locations
- 🇺🇸
Univ of Utah-Solid Organ Transplant, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.